Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonazoid CEUS for Sentinel Nodes in Esophageal Cancer
NCT03578224Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2018
- Primary completion
- Aug 2022
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sonazoid in esophageal cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Accuracy rate of traditional endoscopic ultrasonography (EUS) with suspicious node biopsy and lymphosonography for sentinel node identification up to 2 years. Started Sep 2018; status: completed.
02
Drugs
sonazoid
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03578224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03578224.